Login / Signup

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.

Kaspar RufibachJan BeyersmannTim FriedeClaudia SchmoorRegina Stegherr
Published in: Trials (2024)
The choice of the estimator of the cumulative AE probability and the definition of CEs are crucial. Whenever varying follow-up times and/or CEs are present in the assessment of AEs, SAVVY recommends using the Aalen-Johansen estimator (AJE) with an appropriate definition of CEs to quantify AE risk. There is an urgent need to improve pertinent clinical trial reporting guidelines for reporting AEs so that incidence proportions or one minus Kaplan-Meier estimators are finally replaced by the AJE with appropriate definition of CEs.
Keyphrases
  • clinical trial
  • clinical practice
  • adverse drug
  • risk factors
  • randomized controlled trial
  • emergency department
  • study protocol
  • electronic health record